

Prof. İBRAHİM HALİL GÜLLÜ

Personal Information

Email: ibrahimhalil.gullu@hacettepe.edu.tr

Web: <https://avesis.hacettepe.edu.tr/ibrahimhalil.gullu>

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **The Relationship Between Microplastics and Nanoplastics with Cancer: An Emerging Health Concern**
Yazarkan Y., Sonmez G., Tenekeci A. K., AKSOY E. A., GÜLLÜ İ. H.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, no.2, pp.102-112, 2024 (SCI-Expanded)

Refereed Congress / Symposium Publications in Proceedings

- I. **Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).**
Akyıldız A., Guven D. C., Koksall B., Karaoglan B. B., Salim D. K., Sutcuoglu O., Erciyestepe M., Alan O., Taban H., Yildirim N., et al.
Special Clinical Science Symposia, ELECTR NETWORK, 29 May 2024
- II. **Adjuvan Yoğunluk Ayarlı Radyoterapi Uygulanan Baş-Boyun Kanserli Olgularda Tedavi Sonuçlarımız.**
YÜCE SARI S., CENGİZ M., YAZICI G., ELMALI DOĞAN A., BEDÜK Ç. S., GÜLLÜ İ. H., AKSOY S., ÖZYİĞİT G.
13.Ulusal Radyasyon Onkolojisi Kongresi, Turkey, 27 April - 01 May 2018
- III. **Baş-Boyun Melanomlarında Radyoterapi Sonuçlarımız**
YÜCE SARI S., YAZICI G., CENGİZ M., YILMAZ M. T., AKSOY S., GÜLLÜ İ. H., ÖZYİĞİT G.
13. ULUSAL RADYASYON ONKOLOJİSİ KONGRESİ, Turkey, 27 April - 01 May 2018
- IV. **Definitif Radyoterapi Uygulanan Lokal İleri Evre Larinks Kanserli Hastalarda Hematolojik Parametrelerin Sağkalım Üzerine Prognostik Etkisi**
YÜCE SARI S., CENGİZ M., GÜLTEKİN M., SÜSLÜ N., YAZICI G., HAYRAN K. M., GÜLLÜ İ. H., ÖZYİĞİT G.
22. UKK, Turkey, 19 - 23 April 2017
- V. **Survival and Larynx Preservation Rates after Definitive Radiotherapy A Single Center Experience**
CENGİZ M., YÜCE SARI S., GÜLTEKİN M., SÜSLÜ N., AKSOY S., KUŞCU O., ÖZYİĞİT G., HOŞAL Ş., HAYRAN K. M., GÜLLÜ İ. H.
ECHNO 2016, Budapest, Hungary, 7 - 10 September 2016
- VI. **The impact of the total size of lesions in multifocal multicentric breast cancer on survival**
Karakaş Y., DİZDAR Ö., Akın S., ATEŞ Ö., ŞENDUR M. A. N., AKSOY S., GÜLLÜ İ. H., ÖZİŞİK Y. Y., ALTUNDAĞ M. K.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- VII. **Modified docetaxel cisplatin and fluorouracil therapy as a first line treatment for patients with recurrent metastatic squamous cell carcinoma of the head and neck cancer a retrospective study**
DEMİRCİ N., AKSOY S., ÖZDEMİR N., Babacan T., ERDEM G. U., BOZKAYA Y., ZENGİN N., GÜLLÜ İ. H.
2016 ASCO Annual Meeting, 29 May - 03 June 2016
- VIII. **Radiation Therapy Results of Patients With Adenoid Cystic Carcinoma**
GÜLTEKİN M., CENGİZ M., Sari S. Y., HOŞAL Ş., YAZICI G., SÜSLÜ N., Can O. B., GÜLLÜ İ. H., ÖZYİĞİT G.
57th Annual Meeting of the American-Society-for-Radiation-Oncology (ASTRO), San-Antonio, Northern Mariana Islands, 18 - 21 October 2015, vol.93
- IX. **Comparison of three different induction regimen in nasopharyngeal cancer: CF versus DC versus**

DCF.

Kertmen N., Aksoy S., Cengiz M., Yazici G., Keskin O., Babacan T., Sarici S. F., Akin S., Altundag K., Gullu I. H.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32

- X. **Early stage "T2N0" breast cancer: Does it consist two different "T2" stages?**
Arslan C., Sahin U., Kizilarlanoglu C., Solak M., Gullu I. H., Ozisik Y., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XI. **Outcomes of patients with HER2-negative breast cancer with central nervous system metastasis treated with capecitabine.**
Altundag K., Aksoy S., Sendur M. A. N., Guler E. N., Gullu I. H., Ozisik Y. Y.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XII. **Comparison of ER, PR, HER2 in primary and paired relapsed/metastatic lesions of metastatic breast cancer patients**
SARI E., Guler G., HAYRAN K. M., Altundag K., GÜLLÜ İ. H., Ozisik Y.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XIII. **Comparison of serum levels of CEA and CA 15-3 in triple-negative breast cancer at the time of metastases and serum levels at the time of first diagnosis**
Dede D. S., Aksoy S., Bulut N., Dizdar O., Arik Z., Gullu I., Ozisik Y., Altundag K.
45th Annual Meeting of the American-Society-of-Clinical-Oncology, Florida, United States Of America, 29 May - 02 June 2009, vol.27
- XIV. **Characteristics of breast cancer patients with central nervous system metastases and factors associated with survival after development of central nervous system metastasis**
Harputluoglu H., Dizdar O., Aksoy S., Kilickap S., Dede D. S., Ozisik Y., Guler N., Barista I., Gullu I., Selek U., et al.
30th Annual San Antonio Breast Cancer Symposium, San-Antonio, Northern Mariana Islands, 13 - 16 December 2007, vol.106
- XV. **Serum LDH level is a prognostic factor in locoregionally advanced nasopharyngeal carcinoma (NPC) patients treated with chemoradiotherapy**
Turen S., Ozyar E., Altundag K., Gullu I., Atahan I.
23rd Annual Meeting of the European-Society-for-Therapeutic-Radiology-and-Oncology (ESTRO 23), Amsterdam, Netherlands, 24 - 28 October 2004, vol.73
- XVI. **Clinicopathological features and outcome of primary gastric lymphoma: A series of 73 cases**
Oyan B., Tekuzman G., Barista I., Kars A., Turker A., Ozisik Y., Guler N., Baltali E., Yalcin S., Gullu I.
40th Annual Meeting of the American-Society-of-Clinical-Oncology, Louisiana, United States Of America, 5 - 08 June 2004, vol.22

Metrics

Publication: 46

Citation (WoS): 208

Citation (Scopus): 117

H-Index (WoS): 8

H-Index (Scopus): 3